University of Tasmania, Centre for Law and Genetics, Faculty of Law, Hobart, Australia.
S-02, Scientist Hostel, Chauras campus, Srinagar Garhwal, Uttarakhand 246174, India.
Int J Biol Macromol. 2022 Oct 31;219:1208-1215. doi: 10.1016/j.ijbiomac.2022.08.169. Epub 2022 Sep 1.
The recent outbreak of one of the RNA viruses (2019-nCoV) has affected most of the population and the fatalities reported may label it as a modern-day scourge. Active research on RNA virus infections and vaccine development had more commercial impact which leads to an increase in patent filings. Patents are a goldmine of information whose mining yields crucial technological inputs for further research. In this research article, we have investigated both the patent applications and granted patents, to identify the technological trends and their impact on 2019-nCoV infection using biotechnology-related keywords such as genes, proteins, nucleic acid etc. related to the RNA virus infection. In our research, patent analysis was majorly focused on prospecting for patent data related to the RNA virus infections. Our patent analysis specifically identified spike protein (S protein) and nucleocapsid proteins (N proteins) as the most actively researched macromolecules for vaccine and/or drug development for diagnosis and treatment of RNA virus based infectious diseases. The outcomes of this patent intelligence study will be useful for the researchers who are actively working in the area of vaccine or drug development for RNA virus-based infections including 2019-nCoV and other emerging and re-emerging viral infections in the near future.
最近一种 RNA 病毒（2019-nCoV）的爆发已经影响了大部分人群，报告的死亡人数可能将其标记为现代瘟疫。对 RNA 病毒感染和疫苗开发的积极研究具有更大的商业影响，这导致专利申请数量的增加。专利是信息的金矿，挖掘这些信息可以为进一步的研究提供关键的技术投入。在这篇研究文章中，我们调查了专利申请和已授权专利，以确定使用与生物技术相关的关键字（如基因、蛋白质、核酸等）与 RNA 病毒感染相关的技术趋势及其对 2019-nCoV 感染的影响。在我们的研究中，专利分析主要集中在寻找与 RNA 病毒感染相关的专利数据。我们的专利分析特别确定了刺突蛋白（S 蛋白）和核衣壳蛋白（N 蛋白）作为最活跃的研究大分子，用于开发疫苗和/或药物，以诊断和治疗基于 RNA 病毒的传染病。这项专利情报研究的结果将对那些积极从事基于 RNA 病毒的传染病（包括 2019-nCoV 和其他新出现和重新出现的病毒感染）的疫苗或药物开发领域的研究人员有用。
